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388Significance of Increased Blastic-Appearing Cells in
Bone Marrow Following Myeloablative Unrelated Cord
Blood Transplantation in Adult Patients
Pau Montesinos,1 Adriana Gascon,1 David Martınez-Cuadron,1 Marıa-Leonor Senent,1
Lourdes Cordon,1 Jaime Sanz,1 Amparo Sempere,1 Marıa Lopez-Pavıa,1
Rebeca Rodrıguez-Veiga,1 Marıa J. Hurtado,1 Federico Gomis,1 Guillermo Martın,1
Ignacio Lorenzo,1 Javier Palau,1 Marıa D. Planelles,2 Luis Larrea,2 Nelly Carpio,1
Mariluz Perez-Sirvent,1 Miguel A. Sanz,1,3 Guillermo F. Sanz1An abnormal increase of nonleukemic blastic-appearing lymphocytes in bone marrow (BM) specimens has
been reported after unrelated cord blood transplantation (UCBT). This study analyzed the incidence, chro-
nology, biological features, and clinical significance of elevated numbers of these cells in a series of 165 con-
secutive adult patients demonstrating myeloid engraftment after myeloablative UCBT in a single institution.
The patients’ BM samples were routinely evaluated by cytomorphology at different time points after UCBT.
When$5% of blastic-appearing cells were detected by cytomorphology in the BM, samples were also eval-
uated by multiparametric flow cytometry to characterize these cells. Systematic chimerism analyses of BM
samples using PCR amplification of short tandem repeat markers were performed. Forty-three patients
(cumulative incidence, 26.1%) demonstrated $5% of nonmalignant blastic-appearing cells in BM after
a median of 101 days after UCBT (range, 28-377 days). All of these patients had full-donor chimerism and
a clinical course without leukemic relapse. Multiparametric flow cytometry analyses performed in 36 of
the 43 patients showed a polyclonal expansion of B lymphocytes with a broad spectrum of maturation stages.
An increased number of nonmalignant blastic-appearing cells was significantly associated with a high number
of lymphocytes infused at the time of UCBTand with low rates of acute and chronic extensive graft-versus-
host disease, suggesting a potential immunoregulatory role of these cells. The observation of $5% nonma-
lignant blastic-appearing cells in BM samples after myeloablative UCBT is frequent, and these should be
distinguished from malignant blasts.
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Abnormal expansion of na€ıve B lymphocytes has
been reportedafterunrelatedcordblood transplantation
(UCBT) [1,2]. In some cases, the posttransplantation
bone marrow (BM) specimens may contain immature
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6/j.bbmt.2011.11.008to distinguish frommalignant blasts and raise a concern
about possible relapsed acute leukemia [1-3]. Although
this phenomenon is apparently associated with
allogeneic hematopoietic stem cell transplantation
(HSCT) fromcordbloodprogenitors [3], data regarding
the abnormal increase of blastic-appearing lymphocytes
in the setting of UCBT remain limited. Thus, an exam-
ination of the incidence, chronology, biological features,
and clinical significance of an increased number of
lymphoblast-like cells in BM after UCBT is warranted.
The present study aimed to evaluate the incidence
of an increased percentage of nonleukemic blasts in the
BM after myeloid engraftment in 165 consecutive
adult patients undergoing myeloablative UCBT at
a single center. BM specimens were also examined
by multiparametric flow cytometry (MPFC) to charac-
terize the immature blastic-appearing cells. The
factors associated with the occurrence of increased
nonleukemic blasts, as well as the possible impact of
Biol Blood Marrow Transplant 18:388-395, 2012 389Increased Blastic-Appearing Cells in BM After UCBTthis increase on posttransplantation outcomes, were
analyzed.MATERIALS AND METHODS
Patients and Transplantation Characteristics
Between May 1997 and May 2010, XXX adults
with hematologic malignancies underwent UCBT at
Hospital Universitari i Politecnic La Fe, Valencia,
Spain. All patients included in the study had myeloid
engraftment, defined as more than 3 days with an abso-
lute neutrophil count .0.5  109/L with full-donor
chimerism. All patients provided informed consent in
accordance with institutional guidelines. The trans-
plantation protocols were approved by the hospital’s
Research Ethics Board and conformed to the Declara-
tion of Helsinki. Patients undergoing UCBT with
a reduced-intensity conditioning regimen were ex-
cluded from the study. All UCBTs were performed
on a single unit in the hospital. No graft manipulation
was performed. Donor–recipient matching was based
on low-resolution HLA typing for HLA-A and
HLA-B and on high-resolution typing for HLA-
DRB1. Early disease stage at UCBT was defined as
chronic myelogenous leukemia in the chronic phase,
acute leukemia in first or second complete remission,
myelodysplastic syndrome untreated or in complete
remission, and lymphoma in complete remission.
Preparative Regimens and GVHD Prophylaxis
In 58 patients (35%), the conditioning regimen
comprised thiotepa, oral or i.v. busulfan, cyclophospha-
mide, and antithymocyte globulin (ATG) [4]. Of these
58 patients, 27 received horse ATG (Lymphoglobulin;
bio Merieux, Lyon, France), and 31 received rabbit
ATG (Thymoglobulin; Genzyme, Framingham, MA).
The other 107 patients (65%) received a conditioning
regimen composed of i.v. busulfan, fludarabine, and
ATG (Thymoglobulin) [5].
Acute graft-versus-host disease (GVHD) prophy-
laxis comprised cyclosporine plus prednisone in 111
patients (67%) and cyclosporine plus mycophenolate
in the remaining 54 patients (33%). Acute and chronic
GVHD were graded according to published criteria
[6,7]. Cytomegalovirus (CMV) monitoring and
prophylaxis were performed according to previously
reported protocols [8].
BM Analyses
BM samples of patients were routinely evaluated by
cytomorphology at different time points after UCBT
(days128,156,1100,1180, and1365). BM samples
were stained with May-Gr€unwald-Giemsa stain and
viewed under a light microscope by a local pathologist.
A minimum 300-cell differential count was performed
in each case. When an excess of blastic-appearing cells(ie, high nuclear-to-cytoplasmic ratio and uncon-
densed chromatin, with or without granulation or
nucleolus) was detected, samples were evaluated by
MPFC to characterize the blastic-appearing cells. Blas-
tic cells were gated on the basis of their CD341 and
CD45w content and low side light scatter. Immature
blastic-appearing B lymphocytes were discriminated
by MPFC on the basis of the normal B cell maturation
pattern into several stages using a combination of
CD10, CD19, CD20, CD22, CD34, CD38, TdT,
and CD45 antigen surface markers [9,10]. In patients
with antecedents of leukemia, malignant blastic cells
were characterized according to the leukemic blast
phenotype at baseline diagnosis. Chimerism analyses
of BM samples using multiplex PCR amplification
of short tandem repeat markers were performed
systematically at each time point.
Study Definitions and Endpoints
The study’s primary endpoint was the incidence of
increased blastic-appearing cells in BM after UCBT,
defined as$5% of nonmalignant blastic cells detected
on cytomorphology. Relapse of leukemia or myelodys-
plastic syndrome, development of secondary myeloid
neoplasms, and posttransplantation lymphoprolipher-
ative syndrome were excluded at the time of detection
of increased blastic-appearing cells. The differential
diagnosis between nonmalignant blastic-appearing
cells andmalignant blasts was done by chimerism anal-
yses (with full-donor chimerism required for diagno-
sis), MPFC, and cytogenetics or molecular biology
when the baseline hematologic malignancy had a char-
acteristic genetic abnormality. The secondary study
endpoint was time to increased blastic-appearing cells.
Overall survival (OS), nonrelapse mortality
(NRM), risk of relapse (RR), disease-free survival
(DFS), and development of chronic GVHD after
UCBT were assessed as well. All patients were fol-
lowed until death or last follow-up.
Data Collection and Prognostic Factors
Data were collected prospectively and registered.
Twenty-two patient and transplantation characteris-
tics were examined to establish their relationship
with the occurrence of increased blastic-appearing
cells in BM. Demographic data and transplantation
characteristics included age; sex; weight; previous
autologous or allogeneic HSCT; underlying disease;
disease stage; patient CMV serostatus; degree of
HLA mismatch; ABO incompatibility; donor sex,
number of total nucleated and CD341 cells at cryo-
preservation; viability and number of total lympho-
cytes, CD31, CD41, CD81, CD161/561, and
CD191 cells infused; conditioning regimen; type of
ATG used; and acute GVHD prophylaxis. The rate
of increased blastic-appearing cells in BMwas assessed
in relation to the development of acute GVHD.
390 Biol Blood Marrow Transplant 18:388-395, 2012P. Montesinos et al.Statistical Methods
Fisher exact test, the Mann–Whitney U test, and
the Student t-test were used to analyze differences in
the distribution of variables between patient subsets.
Unadjusted time-to-event analyses were calculated
from the date of UCBT. The probabilities of increased
blastic-appearing cells, NRM (all deaths occurring
before relapse), RR, and development of chronic
GVHD were estimated by the cumulative incidence
(CI) method (for marginal probability) to take into
account competing risks, and these were compared us-
ing theGray test [11]. OS andDFS curves were plotted
using the actuarial method of Kaplan and Meier [12],
and the differences between curves were analyzed
using the log-rank test [13]. In the analysis of CI of
increased blastic-appearing cells, death, relapse, and
development of secondary myeloid neoplasm or lym-
phoprolipherative syndrome were considered compet-
ing causes of failure. The characteristics selected for
inclusion in the multivariate analysis were those for
which there was some indication of a significant asso-
ciation in the univariate analyses (P\ .05). Multivari-
ate analysis was performed using the Fine and Gray
model for CI [14]. To avoid time-dependent bias,
only patients surviving more than 365 days after
UCBT were included in the analysis to establish the
relationships between increased blastic-appearing cells
(measured during the first post-UCBT year) and OS,
DFS, RR, NRM, and development of chronic
GVHD. The patient follow-up information was up-
dated in July 2011, and the median follow-up in survi-
vors was 63 months (range, 11-156 months). All
P values reported are two-sided. Computations were
performed using the 3D, 4F, 1L, and 2L programs
from the BMDP statistical library (BMDP Statistical
Software, Los Angeles, CA) [15] and the R 2.10.2 soft-
ware package for CI and the Fine and Gray model.RESULTS
Patients and Transplantation Characteristics
Of 183 unselected consecutive adult patients
undergoing myeloablative UCBT during the study
period, 165 survived for longer than 28 days and
demonstrated myeloid engraftment and thus were
included in our analysis. Table 1 summarizes patient
and transplantation characteristics. In brief, 100 of
the 165 patients (61%) were male, median recipient
age at transplantationwas 32 years (range, 15-52 years),
and median recipient weight at transplantation was
70 kg (range, 37-112), respectively. Twenty-three
patients had undergone previous HSCT (20 autolo-
gous and three allogeneic). Themost frequent underly-
ing diseases were acute myelogenous leukemia (AML)
(36%), acute lymphoblastic leukemia (35%), and
chronic myelogenous leukemia (13%). CMV recipientserostatus was positive in 130 cases (79%). UCBT was
performed at an early disease stage in 67% of the
patients. Donor–recipient matching was 6/6 in 10 pa-
tients, 5/6 in 46 patients, and 4/6 in 109 patients. The
median number of nucleated and CD341cells at cryo-
preservation was 2.88  107/kg recipient body weight
(range, 1.4-7.52  107/kg) and 1.63  105/kg (range,
0.17-6.76  105/kg), respectively.
Incidence and Time of Appearance of Increased
Blastic-Appearing Cells
Forty-three patients had $5% of immature
blastic-appearing cells in BM after UCBT. The CI of
increased blastic-appearing cells was 26.1%, which
occurred at a median of 101 days after UCBT (range,
28-377 days). The distribution of increased blastic-
appearing cells according to the time of BMassessment
was two cases at day 128 (5%), two cases at day 156
(5%), 25 cases at day 1100 (58%), three cases at day
1180 (7%), six cases at day1365 (14%), and five cases
detected on unscheduled BM assessments between day
1110 and day 1170 (11%) (Figure 1). Thirty-three
patients had only one positive result (ie,$ 5% nonleu-
kemic blastic-appearing cells), and 10 patients had
two positive results. No patient had more than two
positive BM results in the first year after UCBT.
Biological Features of Increased Blastic-
Appearing Cells
In the patients with an increased percentage of
blastic-appearing cells after UCBT, the median per-
centage of blastic-appearing cells in BM samples by
cytomorphology was 6% (range, 5%-14%). All 43 pa-
tients had full-donor chimerism (range, 98%-100%)
and a clinical course excluding leukemic relapse.
MPFC analyses were performed in 36 of the 43 pa-
tients (84%). In those patients, the median percentages
of B lymphocytes (CD191 cells) and B lymphoblasts
(CD341/CD191 cells) detected by MPFC were
16.8% (range, 0%-53.8%) and 2.7% (range, 0%-
9%), respectively. In 33 of the 36 patients,MPFC anal-
ysis revealed a polyclonal expansion of B lymphocytes
with a broad spectrum of maturation stages (Figure 2).
In the remaining three patients analyzed by MPFC,
the blastic-appearing cells in the BM morphology
were not correlated with an expansion of B cells; one
patient had immature T cell expansion, and two pa-
tients had an excess of nonmalignant immature mye-
loid cells. In addition, three of the 36 patients had
concomitantly detectable levels of minimal residual
disease detected by MPFC (range, 0.13%-0.33%).
Differential Diagnosis of Increased Blastic-
Appearing Cells
Between days128 and1365 post-UCBT, 19more
patients with$5% blasts detected by cytomorphology
Table 1. CI Rates of Increased Blastic-Appearing Cells According to Patient and Transplantation Characteristics, Univariate and
Multivariate Analyses
Characteristic
Total Patients,
n (%)
Patients with Increased
Blastic-Appearing
Cells, n (%)
1-Year
CI, %
P Value, Univariate
Analysis
Multivariate Analysis,
Hazard Ratio (95%
Confidence Interval)
P Value, Multivariate
Analysis
Overall 165 (100) 43 (100) 26.1
Patient age, years
<30 72 (44) 22 (51) 30.7 .26 NI
$30 93 (56) 21 (49) 22.6
Sex
Male 100 (61) 22 (51) 22.1 .17 NI
Female 95 (39) 21 (49) 32.3
Previous HSCT
No 142 (86) 37 (86) 26.1 .98 NI
Yes 23 (14) 6 (14) 26.1
Diagnosis
ALL 58 (35) 14 (32) 24.1 .36 NI
AML 59 (36) 18 (42) 30.7
CML 21 (13) 2 (5) 9.5
Lymphoproliferative syndrome 13 (8) 4 (9) 30.8
MDS and/or CMPS 14 (8) 5 (12) 35.7
Disease stage at UCBT
Early 110 (67) 34 (79) 31.6 .07 NI
Advanced 54 (33) 9 (21) 17.0
HLA compatibility
6/6 10 (6) 3 (7) 30.0 .69 NI
5/6 46 (28) 10 (23) 21.7
4/6 109 (66) 30 (70) 27.5
Preparative regimen
BU-CY-TT-Lymphoglobulin 27 (16) 1 (2) 3.7 .012 1.23 (0.76-1.98) 0.40
BU-CY-TT-Thymoglobulin 31 (19) 11 (26) 35.5
BU-FLU-TT-Thymoglobulin 107 (65) 31 (72) 29.0
ABO incompatibility
No or minor 125 (76) 31 (72) 24.2 .47 NI
Major 40 (24) 12 (28) 30.0
CMV recipient serostatus
Negative 35 (21) 8 (19) 23.8 .55 NI
Positive 130 (79) 35 (81) 26.9
Cryopreserved CD34+ cells,  105/kg
#1.5 73 (44) 20 (46) 30.1 .56 NI
>1.5 92 (56) 23 (54) 25.0
Infused lymphocytes,  107/kg
#1.5 117 (80) 24 (65) 20.5 .007 1.52 (0.69-3.37) .30
>1.5 30 (20) 13 (35) 43.3
Infused CD3+ cells,  107/kg
#0.6 74 (51) 13 (35) 17.6 .025 0.99 (0.41-2.41) .99
>0.6 70 (49) 24 (65) 34.3
Infused CD8+ cells,  107/kg
#0.2 92 (64) 17 (46) 18.5 .01 1.72 (0.76-3.87) .19
>0.2 52 (36) 20 (54) 38.5
Infused CD19+ cells,  107/kg
#0.2 83 (58) 17 (47) 20.5 .09 NI
>0.2 60 (42) 19 (53) 31.7
GVHD prophylaxis
CsA/prednisone 111 (67) 25 (58) 22.7 .12
CsA/mycophenolate 54 (33) 18 (42) 33.3
Acute GVHD
Grade 0 61 (37) 25 (58) 40.9 <.001 2.17 (1.10-4.26) .025
Grade I-II 70 (42) 13 (30) 18.7
Grade III-IV 34 (21) 5 (12) 14.7
ALL indicates acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; MDS, myelodysplastic syndrome; CMPS, chronic myeloprolipherative
syndrome; CsA, cyclosporine A; BU, busulfan; FLU, fludarabine; TT, thiotepa; CY, cyclophosphamide; NI, not included in multivariate analysis.
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percentage ofmalignant leukemic blasts of 50% (range,
5%-100%). Relapse corresponded to acute lympho-
blastic leukemia in 13 cases and to AML in six cases.
One other patient with 6% BM blasts on day 1174
was diagnosed with posttransplantation Epstein-Barr
virus–associated lymphoma with BM infiltration.Prognostic Factors for Increased Blastic-
Appearing Cells After UCBT
The risk of increased nonmalignant blastic-
appearing cells was higher in patients who did not
develop acute GVHD (P\ .001) and in patients who
received an infused lymphocyte dose .1.5  107/kg
(P 5 .007), an infused CD81 cell dose .0.2  107/kg
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Figure 1. Time distribution of increased blastic-appearing cells in BM
after UCBT.
392 Biol Blood Marrow Transplant 18:388-395, 2012P. Montesinos et al.(P 5 .01), a conditioning regimen including Thymo-
globulin (P 5 .01), or an infused CD31 cell dose
.0.6  107/kg (P 5 .02). There was a trend toward
higher risk in those with early disease stage at UCBT
(P 5 .07) and an infused CD191 cell dose .0.2 
107/kg (P5 .09) (Table 1). Multivariate analysis iden-
tified the absence of acute GVHD (hazard ratio [HR],
2.17; 95% confidence interval, 1.10-4.26; P5 .025) as
the sole independent factor associated with increased
nonmalignant blastic-appearing cells (Table 1). The
CI curves of increased blastic-appearing cells depend-
ing on the development of acute GVHD and infused
lymphocyte dose are shown in Figure 3.
Influence of Increased Blastic-Appearing Cells
on Post-UCBTOutcomes
In patients followed up for at least 1 year after
UCBT (n 5 88), OS, DFS, NRM, and RR at 3 years
did not differ significantly between patients with and
those without increased blastic-appearing cells during
the first year (78%, 75%, 9%, and 18%, respectively,
versus 78%, 75%, 19%, and 7%; P 5 .86, .87, .24,
and .51, respectively). The rate of chronic extensive
GVHD was lower in patients with increased blastic-
appearing cells (18% vs 46%, P 5 .008). Multivariate
analysis identified donor–recipient ABO group incom-
patibility (P 5 .04), development of acute GVHD
(P 5 .03), and absence of increased blastic-appearing
cells (P 5 .005) as independent prognostic factors for
development of chronic extensive GVHD.Figure 2. Example of polyclonal expansion of immature B lymphocytes
after UCBTas detected by MPFC. (A and B) Analysis of the CD191 cell
subpopulation in the BM found high numbers of nonleukemic CD101 B
cells (A) and more mature CD10-/CD201 B cells (B). (C) An abnormally
elevated percentage of CD341/CD191 B lymphoblasts in BM (7.37%)
was also detected.DISCUSSION
Our findings indicate that an increase in the num-
ber of nonmalignant blastic-appearing cells in BM
frequently occurs after myeloablative UCBT in adult
patients. Using MPFC, we demonstrated that this
increase in blastic-appearing cells is correlated with
Figure 3. CI curves of increased blastic-appearing cells in BM after UCBT. (A) CI in patients with and without acute GVHD. (B) CI according to infused
lymphocyte dose.
Biol Blood Marrow Transplant 18:388-395, 2012 393Increased Blastic-Appearing Cells in BM After UCBTan expansion of B lymphocytes with a broad spectrum
of maturation stages. This abnormal expansion of
lymphoblast-like cells in BM was detected mostly at
the BM assessment on day 1100 post-UCBT, but
also occurred at other time points during the first
year after UCBT. Occurrence of increased blastic-
appearing cells in BM was associated with a high num-
ber of cord blood lymphocytes infused at the time of
UCBT and with low rates of acute and chronic exten-
sive GVHD.
To the best of our knowledge, to date, only one
study, by McKenna et al. [3], has analyzed the inci-
dence of increased blastic-appearing or lymphoblast-like cells after UCBT. Those authors found a crude
incidence of 18% in 79 recipients that had undergone
UCBT, similar to the CI of 26% in our series. How-
ever, the incidences in the two studies are not compa-
rable, due to differences in the study populations
(median age, 6.5 years in the series by McKenna
et al. compared with 32 years in our series), variations
in statistical methodology (crude incidence versus CI),
and because the cutoff to consider an increased pro-
portion of blastic-appearing or lymphoblast-like cells
in BM was not defined by McKenna et al. (as opposed
to$5% in our study). Interestingly,McKenna et al. [3]
found that among 79 patients who underwent BM or
394 Biol Blood Marrow Transplant 18:388-395, 2012P. Montesinos et al.peripheral blood HSCT, only one recipient had BM
aspirate with atypical, blast-like cells. We cannot con-
firm that finding, given that our analysis was restricted
to UCBT.
The median time of appearance of increased
blastic-appearing cells in BM of 101 days (range, 28-
377 days) post-UCBT in our series certainly depends
on the scheduled time points for performing routine
BM aspirate analysis in our institution. Nevertheless,
the peak incidence of increased lymphoblast-like cells
in the BM on day 1101 is congruent with the previ-
ously reported early B cell recovery observed after
UCBT [16-20]. McKenna et al. [3] did not specify
the median day of increased blastic-appearing cells in
their series, but they did report the appearance of atyp-
ical cells as early as 60 days after UCBT, with cells
remaining as long as 23 months afterward in some
cases. As far as we know, only two case report studies,
by Shono et al. [1] and Mattei et al. [2], have noted an
earlier presentation of increased atypical lymphoblasts
in BM (on day 130 and day 145, respectively).
In the present study, as in the reports of Shono
et al. [1] and Mattei et al. [2], the increased blastic-
appearing cells in BM after UCBT were mostly char-
acterized by MPFC as an abnormal expansion of
CD191 cells with a wide range of maturation states.
An increased percentage of these cells, called hemato-
gones by some authors [10], has also been reported in
BM specimens after HSCT [21] and after chemother-
apy in pediatric patients [22,23], but it seems to be
especially frequent after UCBT. This phenomenon
might be explained by the increased generative
capacity of human B lymphocyte progenitors from
cord blood compared with adult or pediatric BM
[24]. In contrast to this study, McKenna et al. [3]
reported only the morphological features of
lymphoblast-like cells. The differential BM counts in
patients with increased lymphoblast-like cells had
a median of 3.4% atypical cells in their study, com-
pared with 6% in ours. Of note, we found elevated
median percentages of B lymphocytes (16.8%) and B
lymphoblasts (2.7%) by MPFC that could have been
classified as blastic-appearing cells by local patholo-
gists. Unfortunately, we have not assessed the interob-
server variability for BM blastic-appearing cell
percentages or the percentages of B lymphocytes and
B lymphoblasts by MPFC in patients with \5%
blastic-appearing cells by light microscopy.
Regarding the differential diagnosis between leu-
kemic relapse and abnormal percentages of nonmalig-
nant blasts after UCBT, only 18 of 62 patients (29%)
with$5% blasts in BM were diagnosed with leukemic
relapse, whereas 43 patients (69%) actually had in-
creased nonleukemic blasts. Our data underscore the
importance of performing a complete diagnostic
workup to evaluate BM specimens after UCBT,
including MPFC and chimerism analyses, at least inpatients exhibiting increased blastic-appearing cells.
Of note, the remaining patient with $5% blasts in
BM was diagnosed with posttransplantation lym-
phoma (2%), highlighting that careful differential
diagnosis should also include secondary lymphoid or
myeloid malignancies derived from the donor cells.
To the best of our knowledge, only one previous
study has analyzed the impact of pretransplantation
factors (ie, number of infused total nucleated and
CD341 cells) on an increased percentage of blastic-
appearing cells, and that study did not find any rela-
tionship [3]. In the present study, we found that the
number of infused lymphocytes, particularly CD81
cells, is predictive of increased blastic-appearing cells
during the first year after UCBT, suggesting a poten-
tial role of the lymphocyte innoculum on posttrans-
plantation B cell immune recovery. Nevertheless, the
main variable associated with increased blastic-
appearing cells was the absence of acute GVHD. We
can hypothesize that this relationship might reflect
an inhibitory effect of acute GVHD on B cell reconsti-
tution after HSCT [25,26]. We also found lower rates
of chronic extensive GVHD in patients with increased
blastic-appearing cells, leading us to speculate about
a possible role of B cell subpopulations in immune tol-
erance after UCBT [27]. Interestingly, our univariate
analysis showed that preparative regimens containing
Lymphoglobulin were associated with a lower inci-
dence of increased blastic-appearing cells compared
with regimens containing Thymoglobulin; however,
this variable was removed from the multivariate analy-
sis when acute GVHD was entered. This finding
suggests that the influence of regimens containing
Lymphoglobulin was related, at least in part, to the
higher rates of acute GVHD observed in patients
receiving this preparative regimen (data not shown).
A recent study has suggested that the percentage of
hematogones in the BM after chemotherapy might be
associated with favorable outcomes in patients with
AML [28]. However, we were unable to show such
a prognostic impact after myeloablative UCBT for
hematologic malignancies.
In conclusion, the cytomorphologic detection of
$ 5% blastic-appearing cells in BM samples is a fre-
quent occurrence in adult recipients of myeloablative
UCBT. In most cases, this finding indicates an
increase in nonleukemic B lymphoblasts that should
be distinguished from malignant blasts using MPFC.
Our findings suggest that expansion of immature B
lymphocytes in BM is correlated with low rates of
acute and chronic GVHD after UCBT.ACKNOWLEDGMENTS
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